started · updated
Johnson & Johnson reports positive Impella outcomes in high-risk heart procedures
Clinical analyses presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 symposium indicate positive survival and patient outcomes when using Impella heart pumps during high-risk percutaneous coronary intervention (HRPCI). Data from 1,379 patients across the United States and Europe showed lower in-hospital, 30-day, and 90-day mortality rates compared to results previously reported in the CHIP-BCIS3 study.
Navin Kapur, Chief Medical and Scientific Officer at Heart Recovery, MedTech, Johnson & Johnson, stated that the findings reinforce that outcomes depend on patient selection, procedural approach, and post-procedural management in addition to the device itself. The data, which includes findings from the TRI-GUARD-PCI registry involving patients in Germany, Switzerland, and Austria, suggests that timely support and consistent care protocols are critical for improving outcomes in complex heart procedures.
Entities
Impella · Johnson & Johnson · Navin Kapur · Transcatheter Cardiovascular Therapeutics · United States